首页> 外文期刊>Scientific reports. >Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4
【24h】

Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4

机译:通过抑制TMPRSS4的抗癌细胞侵袭,增殖和存活,新型2-羟基丙烯酰胺衍生物IMD-0354和KRT1853的抗癌活性

获取原文
           

摘要

Elevated expression of transmembrane serine protease 4 (TMPRSS4) correlates with poor prognosis in non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and other cancer patients. Previously, we demonstrated that TMPRSS4 mediates tumor cell invasion, migration, proliferation, and metastasis. In addition, we reported novel 2-hydroxydiarylamide derivatives, IMD-0354 and KRT1853, as TMPRSS4 serine protease inhibitors. Here, we further evaluated the effects of the representative derivatives on TMPRSS4-mediated cellular function and signaling. IMD-0354 and KRT1853 inhibited cancer cell invasion, migration, and proliferation in TMPRSS4-expressing prostate, colon, and lung cancer cells. Both compounds suppressed TMPRSS4-mediated induction of Sp1/3, AP-1, and NF-κB transcription factors. Furthermore, TMPRSS4 promoted cancer cell survival and drug resistance, and both compounds enhanced anoikis sensitivity as well as reduced bcl-2 and survivin levels. Importantly, KRT1853 efficiently reduced tumor growth in prostate and colon cancer xenograft models. These results strongly recommend KRT1853 for further development as a novel anti-cancer agent.
机译:跨膜丝氨酸蛋白酶4(TMPRSS4)的升高表达与非小细胞肺癌,胃癌,结直肠癌,前列腺癌和其他癌症患者不良预后。以前,我们证明TMPRS4介导肿瘤细胞侵袭,迁移,增殖和转移。此外,我们报道了新型的2-羟基亚胺胺衍生物,IMD-0354和KRT1853,如TMPRSS4丝氨酸蛋白酶抑制剂。在这里,我们进一步评估了代表性衍生物对TMPRSSS4介导的蜂窝功能和信号传导的影响。 IMD-0354和KRT1853抑制TMPRSS4表达前列腺,结肠和肺癌细胞中的癌细胞侵袭,迁移和增殖。两种化合物抑制了TMPRS4介导的SP1 / 3,AP-1和NF-κB转录因子的诱导。此外,TMPRS4促进了癌细胞存活和耐药性,并且两种化合物都增强了Anoikis敏感性以及减少的Bcl-2和Survivin水平。重要的是,KRT1853有效地降低了前列腺和结肠癌异种移植模型的肿瘤生长。这些结果强烈推荐KRT1853以进一步发展为新型抗癌剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号